Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Adults with FLT3-ITD AML in first remission underwent hematopoietic cell transplantation (HCT) and were randomly assigned to placebo or 120mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival.